Nuveen LLC Invests $9.03 Million in Enovis Corporation $ENOV

Key Points

• Nuveen LLC acquired a new stake in Enovis Corporation, purchasing 236,299 shares valued at approximately $9 million, representing 0.41% ownership as of their latest SEC filing.
• Multiple institutional investors have increased their positions in Enovis, with hedge funds and institutional investors now owning 98.45% of the company's stock.
• Analysts have recently downgraded their price targets for Enovis, with the average target now at $51.00 and six analysts maintaining a "Buy" rating on the stock.

Nuveen LLC acquired a new position in shares of Enovis Corporation (NYSE:ENOV - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 236,299 shares of the company's stock, valued at approximately $9,029,000. Nuveen LLC owned approximately 0.41% of Enovis at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mariner LLC increased its stake in shares of Enovis by 16.8% in the fourth quarter. Mariner LLC now owns 7,925 shares of the company's stock worth $348,000 after purchasing an additional 1,142 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Enovis by 11.7% in the 4th quarter. First Trust Advisors LP now owns 402,483 shares of the company's stock valued at $17,661,000 after purchasing an additional 42,216 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of Enovis by 9.2% in the 4th quarter. MetLife Investment Management LLC now owns 31,487 shares of the company's stock worth $1,382,000 after buying an additional 2,648 shares during the last quarter. MML Investors Services LLC grew its position in Enovis by 11.3% during the 4th quarter. MML Investors Services LLC now owns 49,157 shares of the company's stock worth $2,157,000 after purchasing an additional 4,978 shares during the last quarter. Finally, Stifel Financial Corp lifted its stake in Enovis by 1.9% during the 4th quarter. Stifel Financial Corp now owns 101,574 shares of the company's stock valued at $4,457,000 after acquiring an additional 1,895 shares during the period. Institutional investors own 98.45% of the company's stock.

Analysts Set New Price Targets

ENOV has been the subject of a number of research reports. Evercore ISI dropped their target price on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Canaccord Genuity Group cut their target price on shares of Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wells Fargo & Company decreased their price target on Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a report on Friday, August 8th. JMP Securities dropped their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Finally, Needham & Company LLC decreased their target price on Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $51.00.

Enovis Trading Up 1.0%

Shares of ENOV stock traded up $0.29 on Friday, reaching $30.88. 934,252 shares of the stock were exchanged, compared to its average volume of 1,151,601. The stock has a 50 day moving average price of $30.06 and a 200 day moving average price of $33.62. The stock has a market cap of $1.77 billion, a PE ratio of -2.17 and a beta of 1.70. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The business had revenue of $564.50 million during the quarter, compared to the consensus estimate of $555.80 million. During the same quarter in the prior year, the company posted $0.62 earnings per share. The firm's revenue was up 7.5% on a year-over-year basis. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities research analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Activity at Enovis

In other Enovis news, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were purchased at an average price of $29.71 per share, for a total transaction of $74,275.00. Following the completion of the purchase, the chief financial officer directly owned 116,729 shares of the company's stock, valued at approximately $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Bradley J. Tandy acquired 3,200 shares of the company's stock in a transaction on Friday, August 22nd. The stock was acquired at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the purchase, the senior vice president directly owned 43,515 shares of the company's stock, valued at approximately $1,366,806.15. This trade represents a 7.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 2.70% of the company's stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.